- Previous Close
0.0070 - Open
0.0080 - Bid 0.0070 x --
- Ask 0.0080 x --
- Day's Range
0.0070 - 0.0080 - 52 Week Range
0.0070 - 0.0360 - Volume
5,530,385 - Avg. Volume
587,570 - Market Cap (intraday)
4.503M - Beta (5Y Monthly) 0.31
- PE Ratio (TTM)
-- - EPS (TTM)
-0.0100 - Earnings Date Feb 20, 2025
- Forward Dividend & Yield --
- Ex-Dividend Date --
- 1y Target Est
--
AdAlta Limited, a clinical stage biotechnology company, discovers and develops protein and cell-based therapeutics by its i-body platform in Australia. Its lead product is AD-214, which is in Phase II clinical trial for the treatment of fibrosis diseases, including idiopathic pulmonary fibrosis, eye fibrosis, and fibrosis diseases of the liver, skin and kidney, as well as for the treatment of age-related macular degeneration. AdAlta Limited has collaborative partnerships with GE Healthcare Technologies Inc to develop i-body enabled PET imaging agents for use in immuno-oncology; and Carina Biotech Pty Ltd to develop CAR-T cell therapies for solid tumor. The company was incorporated in 2006 and is based in Bundoora, Australia.
www.adalta.com.auRecent News: 1AD.AX
View MorePerformance Overview: 1AD.AX
Trailing total returns as of 4/3/2025, which may include dividends or other distributions. Benchmark is S&P/ASX 200 [XJO] (^AXJO) .
YTD Return
1-Year Return
3-Year Return
5-Year Return
Compare To: 1AD.AX
Select to analyze similar companies using key performance metrics; select up to 4 stocks.
Statistics: 1AD.AX
View MoreValuation Measures
Market Cap
4.50M
Enterprise Value
3.03M
Trailing P/E
--
Forward P/E
--
PEG Ratio (5yr expected)
--
Price/Sales (ttm)
--
Price/Book (mrq)
45.31
Enterprise Value/Revenue
--
Enterprise Value/EBITDA
--
Financial Highlights
Profitability and Income Statement
Profit Margin
0.00%
Return on Assets (ttm)
-80.51%
Return on Equity (ttm)
-392.18%
Revenue (ttm)
973.02k
Net Income Avi to Common (ttm)
-4.94M
Diluted EPS (ttm)
-0.0100
Balance Sheet and Cash Flow
Total Cash (mrq)
1.63M
Total Debt/Equity (mrq)
1,638.72%
Levered Free Cash Flow (ttm)
-1.99M